title: Effect of valproic acid through regulation of NMDA receptor-ERK signaling in sleep deprivation rats.
abstract: Although the effect of mood stabilizer valproic acid (VPA) through multiple signaling pathways has been shown, its therapeutic mechanism is still largely unknown. We investigated the effect of VPA (200 mg/kg, every 12 h) in sleep deprivation (SD) rats (72 h), the manic-like animal model, focusing on the N-methyl-D: -aspartic acid (NMDA) receptor and signaling mediators of synaptic plasticity such as extracellular signal-regulated protein kinase (ERK), cAMP response element-binding protein (CREB), B cell chronic lymphocytic leukemia/lymphoma 2 (BCL2), and brain-derived neurotrophic factor (BDNF). SD reduced the expression of the NR2B subunit of the NMDA receptor in the frontal cortex and hippocampus but did not affect the expression of NR1 and NR2A subunits. In comparison, VPA inhibited the SD-induced reduction of NR2B expression in both brain regions. In addition, SD attenuated ERK phosphorylation in the frontal cortex and hippocampus, whereas VPA prevented the attenuation. VPA also protected the SD-induced decrease of CREB phosphorylation, BCL2 expression, and BDNF expression in the frontal cortex but not in the hippocampus. These results indicate that VPA could regulate NMDA receptor-ERK signaling in SD rats, preventing the SD-induced decrease of the expression of NR2B subunit and the activation of ERK signaling mediators such as ERK, CREB, BCL2, and BDNF.
authors.affiliation: Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, 130-701, Republic of Korea.
authors.forename: Hae Jeong
authors.initials: HJ
authors.lastname: Park
authors.forename: Won Sub
authors.initials: WS
authors.lastname: Kang
authors.forename: Jong Woo
authors.initials: JW
authors.lastname: Paik
authors.forename: Jong Woo
authors.initials: JW
authors.lastname: Kim
mesh_terms: D000818:Animals; D018692:Antimanic Agents / Q000494:pharmacology; D005625:Frontal Lobe / Q000187:drug effects* / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D012892:Sleep Deprivation / Q000503:physiopathology*; D014635:Valproic Acid / Q000494:pharmacology*
chemical_list: D018692:Antimanic Agents; C121001:NR2B NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate; D014635:Valproic Acid
references.citation: Curr Opin Neurobiol. 2004 Jun;14(3):311-7
references.pmid: 15194111
references.citation: Nat Rev Drug Discov. 2008 May;7(5):426-37
references.pmid: 18425072
references.citation: Physiol Behav. 1985 Oct;35(4):501-4
references.pmid: 4070421
references.citation: J Affect Disord. 2006 Oct;95(1-3):69-78
references.pmid: 16780960
references.citation: J Neurosci. 2003 Aug 13;23(19):7311-6
references.pmid: 12917364
references.citation: Psychopharmacology (Berl). 2006 Jan;184(1):122-9
references.pmid: 16344985
references.citation: Mol Psychiatry. 2010 Apr;15(4):384-92
references.pmid: 19488045
references.citation: Eur J Pharmacol. 1987 Oct 27;142(3):437-40
references.pmid: 2892686
references.citation: Mol Psychiatry. 2009 Mar;14(3):269-79
references.pmid: 18256615
references.citation: Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1588-96
references.pmid: 20237303
references.citation: Int J Neuropsychopharmacol. 2008 Nov;11(7):947-55
references.pmid: 18477413
references.citation: J Psychiatry Neurosci. 2006 Sep;31(5):326-32
references.pmid: 16951735
references.citation: Curr Opin Psychiatry. 2006 May;19(3):313-23
references.pmid: 16612219
references.citation: Neuron. 2005 Jun 2;46(5):745-60
references.pmid: 15924861
references.citation: Pharmacogenomics J. 2004;4(5):336-44
references.pmid: 15289798
references.citation: Eur Neuropsychopharmacol. 1995;5 Suppl:89-93
references.pmid: 8775765
references.citation: Ann N Y Acad Sci. 2003 Nov;1003:378-80
references.pmid: 14684466
references.citation: J Affect Disord. 2010 Jul;124(1-2):164-9
references.pmid: 19913919
references.citation: Aust N Z J Psychiatry. 2006 May;40(5):386-93
references.pmid: 16683963
references.citation: J Physiol. 2006 Feb 1;570(Pt 3):553-65
references.pmid: 16322058
references.citation: Brain Res. 1991 Mar 29;544(2):345-8
references.pmid: 2039949
references.citation: Neuropharmacology. 2004 Mar;46(4):555-61
references.pmid: 14975679